AASLD EXPO: Modernizing the Approach to Hepatitis D — Who to Test, Who to Treat, and How to Monitor
The AASLD EXPO gives timely, consensus-driven guidance: screen all HBsAg-positive persons once for anti-HDV, confirm viremia with HDV RNA, stage with elastography, and treat compensated chronic HDV with bulevirtide (± peg‑IFN) while monitoring for fibrosis progression and HCC every 6 months.